In a gastric cancer model, triptolide demonstrated the ability to inhibit IL−8 expression induced by IL-1β, in addition to suppressing the activation of the AP-1 axes, mediated by ROS/ERK, and NF-κB, mediated by ROS [126]. Here, IL1B is linked to gastric cancer.